{
  "symbol": "OBIO",
  "company_name": "Orchestra Biomed Hldgs Inc",
  "ir_website": "https://investors.orchestrabiomed.com/",
  "structured_data": [
    {
      "section_name": "Press Releases",
      "links": [
        {
          "title": "Press Releases",
          "url": "https://investors.orchestrabiomed.com/news-events/news-releases",
          "content": "[Skip to content](#lfg-main-content)\n\n[ ![Orchestra BioMed logo](/sites/g/files/knoqqb78086/themes/site/nir_pid7841/dist/images/OBM_Logo_Orange_White_RGB.png) ](https://www.orchestrabiomed.com/)\n\n[ Close ](javascript:;)\n\nInvestor Relations\n\n# News Releases\n\nYear All Years202420232022202120202019201820172016\n\nAll Years\n\n[Orchestra BioMed to Participate in the Piper Sandler 36th Annual Healthcare Conference](/news-releases/news-release-details/orchestra-biomed-participate-piper-sandler-36th-annual)\n\nNovember 26, 2024 \n\nNEW HOPE, Pa., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today announced that company management will present \n\n[Orchestra BioMed Reports Third Quarter 2024 Financial Results and Provides a Business Update](/news-releases/news-release-details/orchestra-biomed-reports-third-quarter-2024-financial-results)\n\nNovember 12, 2024 \n\nNEW HOPE, Pa., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical innovation company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today reported its third quarter 2024 \n\n[Orchestra BioMed to Participate in Jefferies London Healthcare Conference](/news-releases/news-release-details/orchestra-biomed-participate-jefferies-london-healthcare)\n\nNovember 7, 2024 \n\nNEW HOPE, Pa., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today announced that company management will present \n\n[Orchestra BioMed Reports Second Quarter 2024 Financial Results and Provides a Business Update](/news-releases/news-release-details/orchestra-biomed-reports-second-quarter-2024-financial-results)\n\nAugust 12, 2024 \n\nNEW HOPE, Pa., Aug. 12, 2024 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical innovation company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today reported its second quarter 2024 \n\n[Orchestra BioMed Announces Appointment of Cardiovascular Device Industry Expert John Mack to Board of Directors](/news-releases/news-release-details/orchestra-biomed-announces-appointment-cardiovascular-device)\n\nJuly 30, 2024 \n\nJohn Mack brings over 30 years of diverse medical device and healthcare technology experience to the Orchestra BioMed Board of Directors Most recently, Mr. Mack served as Medtronic’s President of Cardiac Surgery; Previous Medtronic roles include Vice President, Business Development, Strategy &\n\n[Orchestra BioMed Announces Further Details on In-Person R&D Day in New York Featuring Key Opinion Leaders to Discuss AVIM Therapy Program in Hypertensive Pacemaker Patients on June 11, 2024](/news-releases/news-release-details/orchestra-biomed-announces-further-details-person-rd-day-new)\n\nJune 4, 2024 \n\nNEW HOPE, Pa., June 04, 2024 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today announced further details on its in-person R&D \n\n[Orchestra BioMed to Participate in Jefferies Global Healthcare Conference](/news-releases/news-release-details/orchestra-biomed-participate-jefferies-global-healthcare)\n\nMay 22, 2024 \n\nNEW HOPE, Pa., May 22, 2024 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today announced that company management will present \n\n[Orchestra BioMed Reports First Quarter 2024 Financial Results and Provides a Business Update](/news-releases/news-release-details/orchestra-biomed-reports-first-quarter-2024-financial-results)\n\nMay 13, 2024 \n\nCompany hosting in-person R&D day event, focused on atrioventricular interval modulation (“AVIM”) therapy, including the unmet need in hypertension, mechanism of action, clinical results and design of the BACKBEAT study in New York City on June 11, 2024 NEW HOPE, Pa., May 13, 2024 (GLOBE NEWSWIRE) \n\n[Orchestra BioMed Announces AVIM Therapy Global Intellectual Property Estate Reaches 110 Issued Patents](/news-releases/news-release-details/orchestra-biomed-announces-avim-therapy-global-intellectual)\n\nApril 30, 2024 \n\nPatent estate covering atrioventricular interval modulation (“AVIM”) therapy includes 37 issued U.S. patents and 73 patents outside the U.S. that collectively comprise over 1,800 claims related to the treatment of hypertension AVIM therapy is currently being studied in the BACKBEAT global pivotal \n\n[Orchestra BioMed to Host In-Person R&D Day in New York on AVIM Therapy Program in Hypertensive Pacemaker Patients on June 11, 2024](/news-releases/news-release-details/orchestra-biomed-host-person-rd-day-new-york-avim-therapy)\n\nApril 30, 2024 \n\nNEW HOPE, Pa., April 30, 2024 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today announced it will host an in-person R&D day \n\nDisplaying 1 - 10 of 66 \n"
        }
      ]
    },
    {
      "section_name": "Events",
      "links": [
        {
          "title": "AVIM Therapy and BACKBEAT Study R&D Day",
          "url": "https://investors.orchestrabiomed.com/events/event-details/avim-therapy-and-backbeat-study-rd-day",
          "content": "[Skip to content](#lfg-main-content)\n\n[ ![Orchestra BioMed logo](/sites/g/files/knoqqb78086/themes/site/nir_pid7841/dist/images/OBM_Logo_Orange_White_RGB.png) ](https://www.orchestrabiomed.com/)\n\n[ Close ](javascript:;)\n\nInvestor Relations\n\n# Event Details\n\n## AVIM Therapy and BACKBEAT Study R&D Day\n\nJun 11, 2024 at 10:00 AM EDT \n\n[Listen to webcast](https://lifescievents.com/event/orchestrabiomed/)\n\n[AVIM Therapy and BACKBEAT Study R&D Day Presentation](/static-files/6bb0806c-01dd-4524-a802-88a727fdfefd \"Orchestra Biomed_AVIM Therapy and BACKBEAT Study RnD Day.pdf\") 5.6 MB\n"
        },
        {
          "title": "Oppenheimer Annual Healthcare MedTech and Services Conference",
          "url": "https://investors.orchestrabiomed.com/events/event-details/oppenheimer-annual-healthcare-medtech-and-services-conference",
          "content": "[Skip to content](#lfg-main-content)\n\n[ ![Orchestra BioMed logo](/sites/g/files/knoqqb78086/themes/site/nir_pid7841/dist/images/OBM_Logo_Orange_White_RGB.png) ](https://www.orchestrabiomed.com/)\n\n[ Close ](javascript:;)\n\nInvestor Relations\n\n# Event Details\n\n## Oppenheimer Annual Healthcare MedTech and Services Conference\n\nMar 12, 2024 at 3:20 PM EDT \n\n[Listen to webcast](https://wsw.com/webcast/oppenheimer34/obio/2767483)\n"
        }
      ]
    },
    {
      "section_name": "Financial Reports",
      "links": [
        {
          "title": "SEC Filings",
          "url": "https://investors.orchestrabiomed.com/financial-filings/sec-filings",
          "content": "[Skip to content](#lfg-main-content)\n\n[ ![Orchestra BioMed logo](/sites/g/files/knoqqb78086/themes/site/nir_pid7841/dist/images/OBM_Logo_Orange_White_RGB.png) ](https://www.orchestrabiomed.com/)\n\n[ Close ](javascript:;)\n\nInvestor Relations\n\n# SEC Filings\n\nGroup - Any -3,4,5Annual FilingsCurrent ReportsMergers & AcquisitionsOtherProxy FilingsQuarterly FilingsRegistration Statements\n\n- Any -\n\nFiling year - Any -20242023202220212020\n\n- Any -\n\n[Filing date ](?items_per_page=10&order=field_nir_sec_date_filed&sort=asc \"sort by Filing date\") | [Form](?items_per_page=10&order=field_nir_sec_form&sort=asc \"sort by Form\") | [Description](?items_per_page=10&order=field_nir_sec_description&sort=asc \"sort by Description\") | Filing Group | View  \n---|---|---|---|---  \nNov 12, 2024 | [10-Q](/sec-filings/sec-filing/10-q/0001558370-24-015313) | Quarterly report which provides a continuing view of a company's financial position |  Quarterly Filings | [View HTML](/node/8226/html) [0001558370-24-015313.pdf](/static-files/d1a72895-f261-4644-b19f-44b31ade7f0a) [0001558370-24-015313.rtf](/static-files/9d140491-b893-4fd9-a73c-50aa78465c9e) [0001558370-24-015313.xls](/static-files/fc00163a-848e-449e-882c-5b52cfdfbde2) [EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA](/sec-filings/sec-filing/10-q/0001558370-24-015313)  \nNov 08, 2024 | [SC 13G](/sec-filings/sec-filing/sc-13g/0002012383-24-003380) | A statement of beneficial ownership of common stock by certain persons |  Other | [View HTML](/node/8221/html) [0002012383-24-003380.pdf](/static-files/d972b57b-f375-421c-9719-7feed384eaa1) [0002012383-24-003380.rtf](/static-files/ffdd4b9b-a0bb-4cfd-8b55-2806815efe81)  \nOct 23, 2024 | [SC 13G](/sec-filings/sec-filing/sc-13g/0002012383-24-001849) | A statement of beneficial ownership of common stock by certain persons |  Other | [View HTML](/node/8206/html) [0002012383-24-001849.pdf](/static-files/2a83798f-7d2a-4e23-b26b-a764ab6a76bc) [0002012383-24-001849.rtf](/static-files/c348f9cf-8d6e-42d5-a031-06a0582a697f)  \nSep 26, 2024 | [4](/sec-filings/sec-filing/4/0001104659-24-103002) | Statement of changes in beneficial ownership of securities |  3,4,5 | [View HTML](/node/8196/html) [0001104659-24-103002.pdf](/static-files/df9c31aa-41bd-4ba5-a973-04359b2a8020) [0001104659-24-103002.rtf](/static-files/4402e8d1-ce70-43fb-bf26-f2173749a26d) [0001104659-24-103002.xls](/static-files/40378d0e-6300-45ed-9d80-5be3445917ab)  \nSep 10, 2024 | [144](/sec-filings/sec-filing/144/0001959173-24-006388) | Filed by \"insiders\" prior intended sale of restricted stock. Non-EDGAR filing |  Other | [View HTML](/node/8171/html) [0001959173-24-006388.pdf](/static-files/9c2d2468-3c6c-4efd-b568-5160f6049f16) [0001959173-24-006388.rtf](/static-files/197aaf9d-9a26-429b-9855-487eb9c766a8) [0001959173-24-006388.xls](/static-files/b8bed374-9dff-46c4-9502-bb4e40921732)  \nSep 10, 2024 | [144](/sec-filings/sec-filing/144/0001959173-24-006395) | Filed by \"insiders\" prior intended sale of restricted stock. Non-EDGAR filing |  Other | [View HTML](/node/8176/html) [0001959173-24-006395.pdf](/static-files/e98e3416-44ae-49cb-9504-13c33651e4dc) [0001959173-24-006395.rtf](/static-files/95c13194-751e-405b-af0f-77b6e89ea93a) [0001959173-24-006395.xls](/static-files/785c7df2-3911-4d19-ab73-c052ac5e9123)  \nSep 10, 2024 | [4](/sec-filings/sec-filing/4/0001104659-24-098692) | Statement of changes in beneficial ownership of securities |  3,4,5 | [View HTML](/node/8181/html) [0001104659-24-098692.pdf](/static-files/ba999dc6-fba1-43b0-8b00-ab5ef05ef360) [0001104659-24-098692.rtf](/static-files/7a5ca92d-cfae-4e1e-9d5d-2033fdebcfe7) [0001104659-24-098692.xls](/static-files/b8181cd1-b6f2-4c3a-aacf-b45cfc1c52e0)  \nSep 10, 2024 | [4](/sec-filings/sec-filing/4/0001104659-24-098693) | Statement of changes in beneficial ownership of securities |  3,4,5 | [View HTML](/node/8186/html) [0001104659-24-098693.pdf](/static-files/63bcb14e-ca78-4a50-9035-4d18fdc8de56) [0001104659-24-098693.rtf](/static-files/c21f43cf-4493-4ec1-81f0-188d3c8264d8) [0001104659-24-098693.xls](/static-files/9f60d913-889f-4744-a369-468146432227)  \nSep 09, 2024 | [144](/sec-filings/sec-filing/144/0001959173-24-006341) | Filed by \"insiders\" prior intended sale of restricted stock. Non-EDGAR filing |  Other | [View HTML](/node/8161/html) [0001959173-24-006341.pdf](/static-files/1e705221-b1ce-489b-8d73-31f0ca8c119a) [0001959173-24-006341.rtf](/static-files/c4960cb8-cb9a-4534-b927-63bcfe015b29) [0001959173-24-006341.xls](/static-files/40a4c412-419e-4761-8202-0b78aaaa65c8)  \nSep 09, 2024 | [144](/sec-filings/sec-filing/144/0001959173-24-006351) | Filed by \"insiders\" prior intended sale of restricted stock. Non-EDGAR filing |  Other | [View HTML](/node/8166/html) [0001959173-24-006351.pdf](/static-files/d4fed41e-b7be-49b9-80ee-26990182de5f) [0001959173-24-006351.rtf](/static-files/96510db8-0627-4d1c-a89f-8644328a0463)  \n  \nDisplaying 1 - 10 of 256 results\n\nData provided by [Kaleidoscope](https://www.kscope.io).\n"
        }
      ]
    }
  ]
}